Eric Chow, MD
Internal Medicine · Rapid City, SDNPI 1841500683
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $899 of the $1,095 with a category attached, or 82.1%. Abiomed accounts for 82.1% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2022 at $899 and has fallen 97.8% since, to $20 in 2025.
Across 10 payments — averaging $109.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$899
- Philips North America LLC$75
- Johnson & Johnson$42
- Novartis$21
- Vertex$20
- Mylan Specialty L.p.$19
- plus $19 from 1 others
What the payments were for
- Travel & lodging$89982%
- Food & beverage$19618%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 2 | $899 |
| Philips North America LLC | 1 | $75 |
| Johnson & Johnson | 3 | $42 |
| Novartis | 1 | $21 |
| Vertex | 1 | $20 |
| Mylan Specialty L.p. | 1 | $19 |
| Pfizer | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$879
How this compares
$1,095 in reported general payments places this provider in the 85th percentile of 178 internal medicine providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 20 | $8,239 |
| Lansoprazole | 13 | $574 |
| Atorvastatin Calcium | 24 | $277 |
| Benztropine Mesylate | 11 | $206 |
| CefuroximeCefuroxime Axetil | 15 | $187 |
| Metoprolol Succinate | 11 | $85 |
| Oxycodone Hcl | 11 | $23 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $19 | $8,23920 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 178 internal medicine providers in South Dakota.
Other internal medicine in Rapid City
- Jennifer MayRapid City$52K
- Richard BeasleyRapid City$25K
- Issam TurkRapid City$14K
- David EvansRapid City$3K
- Matthew WerpyRapid City$873
- Kenneth HartRapid City$372
- David EatonRapid City$357
- Shailesh ThapaRapid City$238
- Marisa MedinaRapid City$228
- Nnamdi NwafoRapid City$170
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.